In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson & Johnson’s Tremfya now ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...

The agency said that between its spinoff from Eli Lilly in 2019 and early 2020, Elanco used discounts and rebates to entice ...

As Chief Commercial Officer at Zoetis, Jamie Brannan will lead an evolved commercial organizational structure that will ...

Monday’s edition of Forbes Daily covers fresh records for S&P 500 and bitcoin, gambling in the UAE, Musk surpasses $300B, open questions for H-1B visa holders and more.